Here are the 10-Q quarterly reports from ZYVERSA THERAPEUTICS INC (ZVSA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ZVSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZVSA filings page.
ZyVersa Therapeutics reported a narrower net loss of $1.8 million for the quarter ended March 31, 2026, compared with $2.3 million a year earlier, as both research and development and general and administrative costs declined. R&D dropped to $57,621 and G&A to $1.25 million, reflecting reduced payroll, manufacturing, consulting and professional fees.
Despite lower expenses, the company remains in a weak financial position. Cash was only $302,660 at quarter‑end against current liabilities of about $14.9 million, resulting in a working capital deficit of roughly $14.1 million and an accumulated deficit near $139.4 million. Management states that these conditions raise substantial doubt about ZyVersa’s ability to continue as a going concern.
To bolster liquidity, ZyVersa raised $1.0 million on February 27, 2026 through convertible notes bearing 10% interest and associated warrants. These instruments are accounted for at fair value, creating a $344,000 day‑one loss and ongoing non‑cash volatility, and add to potential dilution alongside existing warrants, options and preferred shares.
ZyVersa Therapeutics, Inc. reported a sharply higher Q3 2025 loss driven by a major write-down of R&D assets and continued cash burn. Net loss for the quarter was $19.8 million versus $2.4 million a year earlier, and $24.3 million for the nine months versus $8.0 million, largely due to an $18.6 million impairment of in-process research and development after a sustained decline in market capitalization.
Operating expenses rose to $20.8 million in Q3 2025 from $2.3 million, while research and development and general and administrative costs both declined year over year. Cash was $0.5 million at September 30, 2025, with a working capital deficit of $11.8 million and an accumulated deficit of $136.9 million. The company used $4.7 million of cash in operations over nine months and raised $3.7 million via a March 2025 private warrant placement and a July 2025 warrant inducement.
Management states that these conditions raise substantial doubt about ZyVersa’s ability to continue as a going concern. In July 2025, Nasdaq denied continued listing, and the common stock was delisted on October 6, 2025; trading moved to the OTCQB under the symbol ZVSA.